Asia’s OTC Market Stunted By Regulatory Disharmony
Executive Summary
HBW Insight Exclusive: A lack of regulatory harmonization, especially with regards to Rx-to-OTC switch, is holding the Asia-Pacific OTC market back, according to APSMI secretary general, Toshi Tominaga.
You may also be interested in...
South Korea, Not China, Focus For Nordic Consumer Healthcare Industry
HBW Insight speaks to father-daughter entrepreneur duo Hanna Jäderholm and Lars Janson (Skincare Sweden, Mimer Medical and Avia Pharma) about their experience in China and plans to break into the lucrative South Korean consumer healthcare market.
GSK Launches OTC Fluticasone In Japan Following Switch
GSK has launched Flunase in Japan following the switch of fluticasone propionate. JSMI’s Toshi Tominaga gives his assessment of the product’s prospects as an OTC drug.
Japan’s New Rx-To-OTC Procedure Exacerbating Switch Blockage Says JSMI
Japan's new Rx-to-OTC switch procedure has exacerbated a "switch lag" compared with developed countries, says Japan Self-Medication Industry senior adviser Toshi Tominaga in an exclusive interview with HBW Insight. Tominaga proposes improvements such as self-care education for consumers and drug usage advice included by firms in switch applications to help balance the risk-benefit decisions of expert judges.